Valuation: Poxel

Market Cap 12.57M 14.08M 11.61M 10.53M 19.69M 1.34B 20.02M 140M 55.34M 700M 52.84M 51.71M 2.21B P/E 2023
-0.52x
P/E 2024 -0.36x
Enterprise Value 79.65M 89.2M 73.59M 66.69M 125M 8.47B 127M 886M 351M 4.44B 335M 328M 13.99B EV / Sales 2023
33.3x
EV / Sales 2024 11.2x
Free-Float
94.27%
Yield 2023 *
-
Yield 2024 -
1 day-6.97%
1 week+17.16%
Current month+2.00%
1 month-2.58%
3 months-13.30%
6 months-35.66%
Current year-25.90%
1 week 0.15
Extreme 0.1506
0.27
1 month 0.13
Extreme 0.1302
0.27
Current year 0.13
Extreme 0.1302
0.48
1 year 0.13
Extreme 0.1302
0.48
3 years 0.12
Extreme 0.115
0.95
5 years 0.12
Extreme 0.115
5.99
10 years 0.12
Extreme 0.115
13.8
Manager TitleAgeSince
Chief Executive Officer 59 09/06/2026
Director of Finance/CFO - 30/11/2022
Corporate Officer/Principal - 30/04/2023
Director TitleAgeSince
Chairman 48 02/09/2026
Director/Board Member - 30/07/2025
Director/Board Member 59 30/10/2025
Date Insider Type Main position Quantity % Market Cap. Importance
04/02/22 Exercice

Founder

67,000 0.2334%
04/02/22 Exercice

Founder

6,666 0.0232%
30/01/21 Free

Founder

25,263 0.0888%
Change 5-day change 1-year change 3-year change Capi.($)
-6.97%+17.16%-49.67%-50.46% 10.43M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average -0.45%+3.89%+39.59%+136.75% 38.31B
Weighted average by Cap. +0.39%+2.73%+47.57%+158.57%

Financials

2023 2024
Net sales 1.98M 2.22M 1.83M 1.66M 3.1M 211M 3.15M 22.02M 8.72M 110M 8.33M 8.15M 348M 6.64M 7.43M 6.13M 5.56M 10.39M 705M 10.57M 73.77M 29.21M 370M 27.89M 27.3M 1.17B
Net income -35.09M -39.29M -32.42M -29.38M -54.96M -3.73B -55.87M -390M -154M -1.95B -147M -144M -6.16B -18.3M -20.5M -16.91M -15.32M -28.67M -1.95B -29.14M -203M -80.56M -1.02B -76.93M -75.29M -3.21B
Net Debt 46.42M 51.99M 42.89M 38.86M 72.71M 4.93B 73.91M 516M 204M 2.59B 195M 191M 8.15B 67.08M 75.12M 61.97M 56.16M 105M 7.13B 107M 746M 295M 3.74B 282M 276M 11.78B
Projected Income Statement - Annual - Poxel
Logo Poxel
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan.
Employees
5
Date Price Change Volume
23/10/26 €0.1734 -6.97% 544,304
22/10/26 €0.1864 -5.38% 419,071
21/10/26 €0.1970 +7.42% 1,727,432
20/10/26 €0.1834 -17.76% 3,848,782
19/10/26 €0.2230 +50.68% 7,667,004
  1. Stock Market
  2. Stocks
  3. POXEL Stock